STAT+: Enhertu pushes into early breast cancer, as antibody-drug conjugates move up the lineSTAT+: Enhertu pushes into early breast cancer, as antibody-drug conjugates move up the line
Enhertu can help patients with breast cancer when given earlier in the disease, according to data presented at the ESMO Conference 2025.
Surgery beats Ozempic for long-term health, Cleveland Clinic findsSurgery beats Ozempic for long-term health, Cleveland Clinic finds
Weight-loss surgery dramatically outperformed GLP-1 medications in improving longevity and reducing heart, kidney, and eye complications for people with obesity and diabetes. Over 10 years, patients lost far more weight and required fewer medications. Experts say surgery continues to offer survival advantages even in the age of potent obesity drugs. Weight-loss surgery dramatically outperformed GLP-1 Read More
Woman diagnosed with breast cancer at 27 after almost ignoring symptomWoman diagnosed with breast cancer at 27 after almost ignoring symptom
Marissa Coreno didn’t think anything about the lump under her armpit at first, until an ultrasound showed something worrying.
Woman diagnosed with breast cancer at 27 after almost ignoring warning signWoman diagnosed with breast cancer at 27 after almost ignoring warning sign
Marissa Coreno thought the bump in her armpit was nothing, but colleagues encouraged her to check it out. Tests found Stage II breast cancer. Coreno underwent aggressive treatment — and found love along the way.
STAT+: Roche, Celcuity detail successful advanced breast cancer studiesSTAT+: Roche, Celcuity detail successful advanced breast cancer studies
Roche and Celcuity each detailed positive advanced breast cancer trials at ESMO, studies that could lead to new approvals.
Oral drug combination extends progression-free survival in advanced ER-positive breast cancerOral drug combination extends progression-free survival in advanced ER-positive breast cancer
Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes giredestrant, a novel, next-generation selective estrogen receptor degrader and full antagonist, compared to a standard combination approach. These findings, from the phase 3 evERA Breast Cancer study, are presented today by Dr. Erica Mayer of Dana-Farber Cancer Institute at the annual meeting of the European Society for Medical Oncology (ESMO) in Berlin, Germany.
Chemical linked to low sperm count, obesity and cancer found in dummies, tests findChemical linked to low sperm count, obesity and cancer found in dummies, tests find
BPA, a synthetic chemical used in production of plastics, found in baby products made by three big European brandsA chemical linked to impaired sexual development, obesity and cancer has been found in baby dummies manufactured by three big European brands.Dummies made by the Dutch multinational Philips, the Swiss oral health specialists Curaprox and the French toy brand Sophie la Girafe were found to contain bisphenol A (BPA), according to laboratory testing by dTest, a Czech consumer organisation. Philips said they had carried out subsequent testing and found no BPA, while Sophie la Girafe said the amount found was insignificant. Continue reading…
Can Ozempic help you cut back on alcohol? Researchers think soCan Ozempic help you cut back on alcohol? Researchers think so
Semaglutide, tirzepatide, and other GLP-1 drugs appear to slow alcohol absorption and blunt its intoxicating effects, according to new research. The study found participants on these medications felt less drunk despite consuming the same amount of alcohol. This could point to a safer, faster-acting way to help people reduce drinking—distinct from traditional treatments that target Read More
Trump says Ozempic will get much cheaper. Novo Nordisk and Eli Lilly shares tumbleTrump says Ozempic will get much cheaper. Novo Nordisk and Eli Lilly shares tumble
Trump’s comments on Ozempic “signal aggressive posturing” in drug price negotiations, an analyst said Trump’s comments on Ozempic “signal aggressive posturing” in drug price negotiations, an analyst said
Estimates of breast cancer risk for pathogenic variants vary by family historyEstimates of breast cancer risk for pathogenic variants vary by family history
Population-based estimates of cumulative breast cancer risk for established pathogenic variants (PVs) vary by family history and potentially modifiable risk factors, according to a study published online Oct. 9 in JAMA Oncology.